Merck isn’t placing all of its oncology bets on Keytruda (pembrolizmab). Last month, the pharma showed how much interest it had in targeted drugs called kinase inhibitors when it spent $2.7 billion to snatch up ArQule.
Today’s announcement of a $50 million collaboration with Astex and Taiho represents a much smaller ante. The collaboration covers preclinical research on small molecule agents targeting cancer-related mutations being conducted by all three companies. This includes the KRAS oncogene, once thought to be an undruggable target.
Interest in inhibiting KRAS has heightened over the past year as Amgen has revealed data from its leading candidate, called AMG 510, which is now in Phase 1/2 study along with Mirati’s MRTX849. Eli Lilly and J&J have initiated early trials of their drugs LY3499446 and JNJ-74699157, respectively.
Merck’s interest in KRAS inhibition is a sign that it believes its biological agent Keytruda, which was on track to hit $11 billion in sales in 2019, could be vulnerable to competition in diseases like lung cancer.
Last month, it released exploratory data from the KEYNOTE-042 trial indicating that in previously untreated patients with non-squamous non-small cell lung cancer (NSCLC) that expresses Keytruda’s target, called PD-1, the immuno-oncology drug alone was able to shrink tumors and delay death or disease progression in KRAS-positive patients better than chemotherapy. The finding prompted Cantor Fitzgerald analyst Louise Chen to say KRAS could “fade like a fad” if the data is confirmed in additional clinical study.
Merck doesn’t seem to think it can ignore targeted KRAS agents, however. Having its own KRAS-targeting drug could serve to secure its leading place in lung cancer, where AMG 510 and MRTX849 have been able to shrink or eliminate tumors in patients.
In Astex, the New Jersey-based big pharma found a partner that has already had some discovery success. Its research led to the successful launch of Novartis’ breast cancer drug Kisqali (ribociclib) and Johnson & Johnson’s urothelial cancer drug Balversa (erdafitinib).
By Jonathan Gardner
Source: Biopharma Dive
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
